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Wolfram syndrome (WS) is a neuro-degenerative autosomal recessive (AR) disorder (OMIM #222300)
caused by mutations in the WFS1 gene on 4p16.1. More than 120 mutations have been identified in WFS1
associated with AR WS, as well as autosomal dominant nonsyndromic low-frequency sensorineural hearing
loss (LFSNHL). WFS1 variants were identified in eight subjects from seven families with WS, leading to the
identification of four novel mutations, Q194X (nonsense), H313Y (missense), L313fsX360 (duplication
frame shift) and F883fsX951 (deletion frame shift), and four previously reported mutations, A133T and
L543R (missense), V415del (in frame triple deletion) and F883fsX950 (deletion frame shift). A mutation
was found in 11/14 disease chromosomes, two subjects were homozygous for one mutation, one subject
was compound heterozygous for two nucleotide substitutions (missense), one subject was compound
heterozygous for a duplication and a deletion (frame shift), and in three families only one mutation was
detected (Q194X and H313Y). All affected individuals shared clinically early-onset diabetes mellitus and
progressive optic atrophy with onset in the first and second decades, respectively. In contrast, diabetes
insipidus was present in two subjects only. Various degrees and types of hearing impairment were
diagnosed in six individuals and cataract was observed in five subjects.
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Introduction
Wolfram syndrome (WS) was first described by Wolfram and
Wagener in 1938 as the association of childhood-onset
diabetes and optic atrophy (OA).1 The acronym, DIDMOAD,
is often used synonymously to WS in order to include four
characteristic clinical abnormalities: diabetes insipidus,
diabetes mellitus (DM), OA, and deafness, among which
childhood-onset DM and OA often are considered sufficient
for a diagnosis of WS. Since the original delineation the
clinical spectrum of WS has, however, been recognized to
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comprise a multi-system neuro-degenerative disorder, which
in addition to the classical four components includes ataxia,
behavioural and psychiatric illness, apnoea, hypogonadism,
and renal tract atonia with hydronephrosis. Mutations have
been reported in a gene, WFS1, which give rise to two
distinct phenotypes: autosomal recessive (AR) WS and the
autosomal dominant low-frequency sensorineural hearing
loss (AD LFSNHL).2–4 Considerable clinical pleiomorphism,
the use of different diagnostic criteria, and a different focus
on clinical details among published reports make it difficult
to compare the frequency of associated abnormalities.
Furthermore, a second genetic locus on chromosome 4q
has been reported accounting for additional clinical varia-
tion including peptic ulcer and a platelet aggregation
defect.5,6 However, the growing number of WS reports with
confirmed WFS1 mutations and the observation of a
correlation between missense WFS1 mutations and varia-
tions in phenotypes offer a basis for establishing a better
understanding of genotype–phenotype correlation.7,8
The WFS1 gene, which was mapped in 19949 and cloned
in 1998,2,10 encodes an 890 amino-acid (aa) endoplasmatic
reticulum-membrane-located protein, wolframin. It has
nine predicted a-helical transmembrane segments and
otherwise no homology to any other recognized protein
domains.2 No ‘classical’ sorting signals can be identified
and it is composed of a cytoplasm located N-terminal and
an ER lumen located C-terminal, but the molecular
function has not been established.11 – 14 The majority of
the WFS1 mutations are located either in the transmem-
brane domains or in the C-terminal of the protein, and the
nature of the mutations seems to have clinical implica-
tions. Only missense mutations are found together with
AD LFSNHL, but both missense, nonsense and frame shift
mutations are present in AR WS and infer that WS is the
result of a complete lack of functional wolframin protein.8
Functional studies of the WFS1 protein have been
published, but the mechanism of its biological function
and the pathophysiological basis is not understood.
Expression of wild-type or mutated WFS1 protein in
Xenopus oocytes induced a novel Ca2þ ion channel-type
activity over the ER membrane,12 and other studies
demonstrated both the orientation in the membrane,
N-glycosylation of the C-terminal part and an oligomeriza-
tion of the WFS1 protein, most likely as a homotetramer, in
the ER membrane.13,14 In the present study, molecular
analysis of the WFS1 gene in seven families with WS
resulted in identification of eight different mutations; one
of these was a de novo mutation occurring independently in
two families, whereas the remaining ones were inherited.
Materials and methods
Patients and families
Patient records were retrieved from the files of The
National Eye Clinic for the Visually Impaired (NEC –
http://www.visaid.dk/) among referrals from the last
25 years. The minimal diagnostic criteria for WS were
early-onset DM and progressive OA with insidious onset
during the first or second decade. All subjects underwent
an ophthalmological examination including slit lamp
assessment and ophthalmoscopy with dilated pupils.
Additional examinations included dynamic visual field
measurements with the Goldmann perimeter, colour
vision tests, and visual evoked potentials. Full-field electro-
retinography (ERG) was performed in one patient
(EE32:II.3). The patients were followed at NEC for various
periods of time between two and 24 years. Additional
medical information was obtained from records at the
departments of ophthalmology, paediatrics, and audiology.
Pure tone audiograms were undertaken only in patients
who had symptoms of hearing impairment. The files
contained only scanty information about family members
and this study did not include a systematic examination of
all family members with regard to vision, endocrine, and
hearing function. No effort was made to retrieve data on
psychiatric disorders or minor manifestations of WS.
Venous blood was drawn from all patients as well as their
parents and siblings if available. The study adhered to the
tenets of the declaration of Helsinki and all subjects gave
written consent to participate in the study.
DNA extraction
Genomic DNA was extracted from whole blood using
standard procedures. Screening of mutations and poly-
morphisms in the normal population was carried on 60
independent persons selected from the Copenhagen
Family Bank.15
PCR amplification and DNA sequencing of the WFS1
gene
All eight exons, the exon–intron sequences, and the
minimal promoter were sequenced in one affected member
of five families; EE31:II.2, EE32:II.3, EE33:II.2, EE76:II.2,
EE77:II.1, and in two affected individuals in one family,
EE34:II.2 and EE34:II.4. The family members EE53:I.1 and
EE53:II.2 were sequenced in the 50 part of exon 8 (the
family has previously been analysed, unpublished data not
presented). Both strands were sequenced and aligned to the
reference sequence GenBank accession no. AF084481 and
AC116517. A minimum of 100 base pairs (bp) of exon–
intron boundaries and at least 120 bp of the minimal
upstream promoter region and 350 bp of the noncoding
30UTR were analysed. Mutations or single-nucleotide
polymorphisms (SNPs) and zygotic status for each change
were noted and mutations confirmed by restriction
enzyme digests. A total of 22 primers were used (Table 1)
and PCR was carried out under standard conditions
according to the enzyme manufacturers’ protocols; Taq
DNA polymerase was purchased from Amersham (Taq DNA
Polymerase), New England Biolabs (USA); AmpliTaq Gold
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DNA Polymerase from Applied Biosystem Industries (USA);
and Platinum Taq DNA polymerase from Invitrogen (USA).
Reactions were carried out in 15 ml volumes containing
buffer according to the manufacturers’ protocols: 2.5 mM
dNTP, 10mM of each primer, 0.008% cresol red (Aldrich),
12% sucrose (w/v), and 50–100 ng template DNA. Standard
reaction conditions for all primers were 951C for 5 min;
then 40 cycles at 951C for 30 s, 56.41C for 30 s, and 721C for
1 min, followed by 5 min at 721C. PCR reactions were
analysed by 2% agarose gel electrophoresis by staining with
ethidium bromide, 1TBE, before sequencing. Both
strands were sequenced directly using the PCR primers
and BigDye version 1.0 sequencing kit (Applied Biosys-
tems) without further modifications on an ABI377 seque-
nator. Sequence data were analysed using standard
software and sequence alignments were carried out using
ClustalW or BLAST, respectively.16,17
Control digests of identified mutations and screening
of control population
Each identified mutation was confirmed by restriction
enzyme digest (New England Biolabs, USA); standard
restriction enzyme digests were carried out using 3–5 ml
PCR products in 20ml volumes. A mismatch primer, 50-
TCAACCCCAAGAAGAAGACG, was constructed for detec-
tion of the mutation c.580C4T in family EE31 and
digested with HgaI (PCR product generated by the
mismatch primer and WFS1-ex5-R), the mutation
c.397G4A in family EE32 was detected after digest with
the endonuclease Fnu4HI (primer pair WFS1-ex4-F and
WFS1-ex4-R), the mutation c.1628T4G also found in
family EE32 was detected by cleavage with the endo-
nuclease SacI (primer pair WFS1_8-2F and WFS1_8-2R), the
mutation c.937C4T in family EE33 was detected by digest
with the endonuclease RsaI (primer pair WFS1_8-1F and
WFS1_8-1R) and in family EE77 with HpyCH4V (same
primer pair). Restriction enzyme digests with MboI con-
firmed the mutation c.2649delC in family EE34 (primer
pair WFS1_8-4F and WFS1_8-4R), the mutation c.937–
941dupCACTG in family EE76 was detected by digest with
the endonuclease BsgI (primer pair WFS1_8-1F and
WFS1_8-1R), and the mutation c.2646–2649delTTTC was
detected by digest with the enzyme MboII (primer pair
WFS1_8-4F and WFS1_8-4R). Digest of 60 normal control
persons was carried out for all new mutations.
Paternity test for family EE33 and EE77
Standard conditions for 33P-end-labelling of the forward PCR
primers were used; gamma-33P-ATP was purchased from
Hartmann Analytic (Germany) and T4-DNA-polynucleotide
kinase from Fermentas (Lithuania). PCR standard conditions
using the end-labelled PCR primer without further purifica-
tion were carried out under the following conditions: 951C,
20 s, 551C, 20 s, and 721C for 30 s for 35 cycles using New
England Taq-DNA polymerase (USA). For family EE33 STS
markers D11S922, D13S170, D13S154, D2S925, D12S78,
D12S1720, D13S328 and for family EE77, marker systems
D14S273, D14S63, D14S611, D7S661, D7S798, D7S2447,
D7S2207, D7S1824, and D10S1697 were used.
Results
Patients
Ten patients, seven females and three males from seven
families (Figure 1) fulfilled the minimal diagnostic criteria.
Consanguinity was known in one family (EE53), the
parents being first-degree cousins. The main clinical data
are summarized in Table 2, from which it appears that DM
was diagnosed in the first decade between 14 months and 8
years of age, followed by the recognition of OA between 1
and 15 years later, a delay of 5.3 years in average. The OA
had an insidious onset and may have been present for
some time until the visual acuity (VA) was affected. After
the diagnosis of DM, most patients had yearly eye
examinations and initially a normal VA was measured.
OA was not suspected and pallor of the optic discs was not
noticed before the corrected VA had dropped to 0.5. The
OA had a slowly progressive course and resulted in a very
low VA o0.02 in patients with follow-up periods of 20–25
years. Diabetic retinopathy was diagnosed in EE31:II.2 after
22 years of diabetes. Despite argon laser photocoagulation,
she developed a proliferative retinopathy with vitreous
hemorrhages during the following years. Another patient,
EE34:II.2, did not develop retinopathy during 29 years of
observation following the diagnosis of DM. Diabetes
insipidus was diagnosed in two patients of ages 8 and 11
Table 1 PCR and sequencing primers for WFS1
Primer name 50 –30 orientation
Length of
PCR product
(bp)
WFS1-ex1-F CGGAGATGTGGAGTGATTGG 432
WFS1-ex1-R GACCTTGTCGGGACTTTGG
WFS1-ex2-F GCATGTGCAGGTCTGAGATT 679
WFS1-ex2-R ACAAAGGTGACAGGTGCAAG
WFS1-ex3-F CACCTCACCCGCATAGAGTT 571
WFS1-ex3-R GCCCAAGATGAGGTGTGAGT
WFS1-ex4-F CACCTTCCTCACCGTGTTTT 578
WFS1-ex4-R ACCAACACAAGCCAAAGAGAA
WFS1-ex5-F CGTCTGGTGGGAGACCAGT 576
WFS1-ex5-R GGTCTCTACAGGAAGGTTCTGG
WFS1-ex6-F CTGAGTCCACCCCAGCTACT 500
WFS1-ex6-R GGTCTACTCCCAGCGTCCA
WFS1-ex7-F CCTGGTCCTCAACCCTCAG 499
WFS1-ex7-R CTCCCGAGGACACATCCTTA
WFS1-ex8-1F AGGGAGGACCACTAGGATGG 735
WFS1-ex8-1R CTTCAGGTAGGGGCAATTCA
WFS1-ex8-2F TATGCCCATTTCCTGCTCTC 794
WFS1-ex8-2R TACTGCTGCCAGGTCAGTGT
WFS1-ex8-3F GTCTGTAGTGTGCCCCTGCT 675
WFS1-ex8-3R GATGGTGCTGAACTCGATGA
WFS1-ex8-4F TTCGACCGCTACAAGTTTGA 783
WFS1-ex8-4R TGTGGAGGTTACACAGATGCTT
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years, and various degrees and types of hearing impairment
were noticed in six patients (Table 2). The remaining four
subjects had no hearing difficulties and audiological
examination was not performed. Among other manifesta-
tions, a high prevalence of cataract was striking. All
cataracts were bilateral, but otherwise they varied with
respect to type and degree. Cataracts were observed in five
individuals from families EE31, EE33, EE34, EE76, and
EE77, respectively. The lenticular opacities had mainly a
posterior subcapsular location, but scattered cortical ele-
ments were also noted. The cataracts were visually insig-
nificant in three subjects, whereas two of the probands
underwent extracapsular cataract extraction on both eyes.
One of these, EE76:II.2, developed cataracts subacutely at
the age of 9 years during a period of 3 months. Refractive
errors varied between – 4.0 Diopters (D) and þ1.5 D, with
one exception: patient EE31:II.2 had refractive values of
þ7.75–1.251801 and þ8.75–1.75151 in her right and
left eye, respectively. Apart from attenuated optic nerves,
MRI was normal in two subjects, EE53:II.2 and EE76:II.2,
and revealed a slender medulla oblongata in patient
EE34:II.2. Two patients, EE53:II.1 and EE77:II.1, were
developmentally retarded. The cause of death was un-
known in two of the three patients who died during the
Figure 1 Pedigrees of seven Danish WS families. (a) Pedigrees for the WS families; a denotes completely sequenced patients; b denotes patients
where only the mutated region is sequenced; c denotes patients analysed by restriction enzyme digest; (b) Digested PCR products separated by gel
electrophoresis; family EE31: digest with HgaI, normal allele 260 bp, c.580C4T allele 234 bp; family EE32: c.397G4A digested with Fnu4HI, normal
allele 73 bp, mutated allele 61 bp, and c.1628T4G digested with SacI, normal allele 416 bp, mutated allele 569 bp; family EE33: digest with RsaI,
normal allele 542 bp, mutant allele 509 bp; family EE34: digest with MboI, normal allele 450 bp, mutated allele 495 bp; family EE76: c.937–
941dupCACTG digested with BsgI, normal allele 151 and 200 bp, mutant allele additional 62 and 143 bp, and c.2646–2649delTTTC digested with
MboII, normal allele 200 bp and mutant allele 185 bp; family EE77: digest with HpyCH4V, normal allele 68 and 143 bp, mutated allele 200 bp. Size
marker M: 50 or 100 bp DNA ladder.
Mutations in the WFS1 gene
L Hansen et al
1278
European Journal of Human Genetics
observation period. An autopsy on patient EE53:II.1 who
died from pulmonary insufficiency due to fulminant
pneumonia showed OA with severe loss of myelinated
nerve fibres, distorted axons with bulbs or torpedo-like
formations, and astrogliosis. Hypothalamus had axonal
bulbs and torpedos with slight microgliosis, and the spinal
cord showed axonal bulbs and amyloid precursor protein
(APP) accumulation in the pyramidal tract. The brain stem
and pons were smaller than average, but no definitive
olivo-ponto-cerebellar atrophy (multiple system atrophy),
as has been described in WS (Henning Laursen, personal
communication).
Family and WFS1 mutations analysis
Family EE31 One novel nonsense mutation, c.580C4T,
Q194X, was found in exon 5. The nucleotide substitution
converts the glutamine CAG codon into the stop-codon
TAG (Table 3). The remaining 193 aa of the N-terminal
represent a truncated WFS1 protein (Figure 2a), which is
likely to be degraded after translation. DNA was available
only from one family member, EE31:II.2 (Figure 1a), and
no second mutation was identified in the WFS1 coding
regions. Micro-deletions of all exons except exon 7 could
be excluded based on the pattern of polymorphisms
(Table 4).
Family EE32 Two missense mutations were identified in
patient EE32:II.3. The mutation c.397G4A, A133T, located
in exon 4, is known to cause WS18,19 and change a small
nonpolar alanine (GCC) in the central part of the
cytoplasmatic domain into a hydrophilic polar uncharged
threonine (ACC, Figure 2a). The second mutation
c.1628T4G, L543R, is located in exon 8 and changes a
hydrophobic nonpolar leucine (CTC) in the sixth trans-
membrane domain into a polar charged basic arginine
residue (CGC, Figure 2a). L543R is known to cause WS20
most likely due to impairment of a proper insertion of the
protein into the ER membrane. Analysis in the parents
disclosed A133T to be paternal and L543R to be maternal
(Figure 1a, data not shown).
Family EE33 Only one mutation, c.937C4T, H313Y,
located in exon 8 was identified in person EE33:II.2. The
mutation is novel and changes the basic polar charged
histidine (CAC) located in the border region of the first
transmembrane domain into the aromatic bulky polar
uncharged tyrosine (TAC). This amino-acid change may
impair integration of WFS1 protein into the ER membrane
(Figure 2a). The mutation was not found in any of the
parents, for which reason H313Y may be considered a
de novo mutation (Figure 1b). Proof of paternity was
Table 2 Clinical synopsis
Family Patient
Year of
birth Sex
Consan-
guinitya
Diabetes
mellitus,
age at
diagnosisa
Diabetes
insipidus,
age at
diagnosisa
Optic
atrophy,
age at
diagnosis
(years)a
Hearing
deficiency, age at
diagnosisa
Other
manifestations
Age at
death
EE31 II.2 1955 F NI 5 years No 16 NI Retarded puberty
cataract diabetic
retinopathy
45
II.3 1957 F NI 7 years No 10 NI Cataract 35
EE32 II.3 1991 F No 7 years 11 years 9 HI, 6 yearsb None F
EE33 II.2 1995 F No 14 months No 6 Profound HI, 2
monthsc
Cataract growth
retardation
F
EE34 II.2 1963 M NI 4 years No 19 NI NI F
II.4 1965 M NI 8 years No 12 NI Abnormal EEG F
EE53 II.1 1980 F Yes 4 years No 8 Mild conductive
HI at age 13 years
Growth
retardation
Mild MR
Retarded puberty
Celiac disease
Otitis media
18
II.2 1983 F Yes 6 years No 7 HI, 7 yearsd Tubar occlusion
Epilepsy
Growth
retardation
F
EE76 II.2 1985 F No 7 years 8 years 11 HF, 13 years Cataract F
EE77 II.1 1981 M NI 4 years No 8 Congenital
profound hearing
impairment 2
years
Moderate MR
Abnormal
EEG Cataract
F
aHI – hearing impairment, HF – high-frequency hearing impairment, NI – no information, MR – mental retardation.
b30–60 dB HL (hearing level) at 6000 and 8000 Hz. Informal audiological examination.
cOAE (oto acoustic emissions) absent at age 2 years uses sign language.
dAt age 14 years 20 dB HL at 6000 Hz and 60 dB HL at 8000 Hz. No examination since age 14 years.
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established by seven different STS marker systems (see
materials and methods). Micro-deletions of all exons
except exon 7 can be excluded based on polymorphism
pattern.
Family EE34 The novel mutation c.2649delC,
F883fsX953, was found on both alleles in persons EE34:II.2
and EE34:II.4. The mutation leads to a frame shift and a
new 951 aa WFS1 protein product, that is expanded in the
ER-located domain. The mutation may interfere with
transport across and integration into the ER membrane.
The frame shift c.2649delC mutation is located in the
polythymine repeat 19 nucleotides from the genuine stop
codon and the consequence of the mutation is analogous
to c.2646–2649delTTTC (F883fsX950) found in EE76 and
other mutations reported in the polyphenylalanine repeat
causing WS.10,18,19 Analysis of the family revealed that one
sister (EE34:II.1) and both parents (EE34:I.1 and EE34:I.2)
were heterozygous carriers, whereas one sister (EE34:II.6)
harboured the wild-type allele on both chromosomes
(Figure 1b).
The two patients, EE34:II.2 and EE34:II.4, showed no
DNA differences and might be related, despite our missing
family information about a possible parental consangui-
nity (Tables 2 and 4).
Family EE53 Patient EE53:I.1 was heterozygous and
EE53:II.2 was homozygous for the mutation c.1243–
1245delGTC, V415del, in accordance with the known
parental consanguinity (Figure 1b). We have deduced the
carrier state of the deceased mother who was unavailable
for mutation analysis (Figure 1). The mutation is located in
Table 3 Mutations found in the WFS1 gene
ID
family Exon Nucleotide changea
Amino-acid
changeb
Type of
mutation
Protein
domaina Zygosity
Number of
control
analysed Type of mutation Reference
EE31 Ex-5 c.580C4T Q194X Nonsense CD1 Heterozygote 60 Inactivating This study
EE32 Ex-4 c.397G4A A133T Missense CD1 Compound
heterozygote
None Noninactivating, 16 – 18
Ex-8 c.1628T4G L543R Missense TM6 Noninactivating
EE33 Ex-8 c.937C4T H313Y Missense TM1 Heterozygote 60 Noninactivating This study
EE34 Ex-8 c.2649delC F883fsX951 Deletion ER5 Homozygote 60 Inactivating This study
c.2649delC F883fsX951
EE53 Ex-8 c.1243–1245delGTC V415del Deletion TM3 Homozygote None Inactivating 20,22
c.1243–1245delGTC V415del
ER76 Ex-8 c.937–941dupCACTG L315fsX360 Insertion TM1 Compound None Inactivating This
c.2646–2649delTTTC F883fsX950 Deletion ER5 heterozygote Inactivating study,9,16,19
EE77 Ex-8 c.937C4T H313Y Missense TM1 Heterozygote 60 Noninactivating This study
aEndoplasmatic reticulum domain; TM – transmembrane domain with a-helix; CD – cytoplasmatic domain.
bThe nomenclature for numbering of changes at nucleotide or amino-acid level is according to general rules,34 reference sequence AF084481ER.
Figure 2 Mutations and polymorphisms in relation to the primary and secondary structure of wfs1. (a) The cytoplasmatic regions are yellow, the
endoplasmatic regions are green and the transmembrane a-helices are blue, the mutations are red and nonsynonymous amino-acid changes are blue.
(b) A total of 15 mutation-surrounding amino acids from six different species. The transmembrane domains are boxed; identical amino acids are
marked by an asterisk, and conserved amino acids by a colon. Human – Homo sapiens, NP_005996; chimp – Pan troglodytes, protein prediction from
contig AADA1090020; rat - Rattus norvegicus, NP_114011; mouse – Mus musculus, NP_035846; chick – Gallus gallus, protein prediction from contig
AADNO1046637; and fugu – Takifugu rubripes, protein prediction from scaffold_2015.35,36
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exon 8 and the deleted amino acid positioned in the third
transmembrane domain. V415del is previously described
in combination with WS,20,21 and most likely affects
integration of wfs1 into the membrane.
Family EE76 EE76:II.2 was compound heterozygous,
carrying the mutations c.937–941dupCACTG, L313fsX360
and c.2646–2649delTTTC, F883fsX950 in trans (Figure 1b,
Table 3). The c.937–941dupCACTG mutation was found
in the father and brother, both healthy, whereas c.2646–
2649delTTTC mutation was only found in the affected
person. The deceased mother was unavailable for mutation
analysis. The 5-bp duplication results in a frame shift at
L315 and extension of wfs1 into a 359 aa fusion protein,
which presumably is degraded after translation. The four
base deletion results in a frame shift at F883 and a 949 aa
fusion protein, and the mutation is analogous to the
c.2649delC mutations in family EE34 and other reported
WS mutations in the polyphenylalanine.10,18,21
Family EE77 EE77:II.1 carried the mutation, c.937C4T,
H313Y, which is identical to the mutation identified in the
Table 4 Single-nucleotide polymorphisms in the WFS1 gene
Family: person
EE31 EE32 EE33 EE34 EE76 EE77
Region in
the WFS1
gene Descriptiona
Amino-
acid
changeb Domain II.2 II.3 II.2 II.2;II.4 II.2 II.1
Associated with
disordersc
Reference or
acc. number
for SNP’sd
Intron1 Ivs1+85T4C F F CT CT CT CC CT CT ? rs6830765
Ivs1131T4C F F CT TT CT CC TT TT ? This study
Intron2 Ivs2+90A4G F F AG GG AG GG AG AG ? 26
Intron3 Ivs3120C4T F F CT TT CT CC CT CT ? rs4688989
Intron4 Ivs4105G4C F F GG CC GG GG GG GG ? rs5018648
Ivs415T4C F F CT CC CT TT CT CT ? This study
Ivs49G4A F F GA AA GA GG GA GA ? 3,4
Exon 6 c.684C4G R228R CD1 CG CC CG GG CC CC Not associated
with any disorders
rs1801213,
rs7672995
Intron6 Ivs6+114G4A F F GA AA GA GG AA AA ? rs4308430
Ivs6+131C4T F F CT CC CT CC TT TT ? This study
Ivs6104-
101delTCTT
F F NN NN NN deldel NN NN ? 26e, this
study
Exon 8 c.997A4G I333V TM1 AG GG AG AA AG AG Not associated rs1801212
IleVal ValVal IleVal IleIle IleVal IleVal with any disorders
c.1185C4T V395V CD2 CT CC CT CC CT CT Diabetes mellitus
combined with
deafness
rs1801206
c.1500T4C N500N TM5 CT CC CT TT CT CC Not associated
with any disorders
rs1801214
c.1832A4G H611R TM8 AG
HisArg
GG
ArgArg
AG
HisArg
GG
ArgArg
AG
HisArg
GG
ArgArg
Type I and II
diabetes, diabetes
mellitus, diabetes
mellitus combined
with deafness,
suicidal tendency
rs734312
c.2433G4A K811K ER5 GA GG GA GG GA GG Diabetes mellitus,
diabetes mellitus
combined with
deafness
rs1046314
c.2565G4A S855S ER5 GA AA GA GG GA AA Diabetes mellitus,
diabetes mellitus
combined with
deafness
rs1046316
c.2720C4T F F CT TT CT CC TT TT ? rs1046317
c.2764T4C F F TC CC TC TT TC TC ? rs1046319
c.2822G4A F F GA GG GA AA GA GG ? rs1046320
aThe nomenclature for numbering of polymorphisms at nucleotide and amino-acid level is according to general rules.34
bER – endoplasmatic reticulum domain; TM – transmembrane domain with a-helix; CD – cytoplasmatic domain.
cLesperance.24
dAccessions numbers refers to GenBank SNP database.
eThe deletion might be identical to the one reported.22,24
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unrelated family EE33. None of the parents carried this
mutation (Figure 1b) implicating a de novo mutation, and
no other mutation was detected in the WFS1 coding
regions. Proof of paternity was established by 12 different
STS marker systems (see materials and methods).
Single-nucleotide WFS1 polymorphisms
Small deletions or SNPs were identified both in intronic
and exonic regions in five of the seven families (Table 4). In
family EE34, the two sequenced patients were homozygous
and in the consanguineous family EE53 the affected
patient was homozygous in the sequenced regions. In
total, 12 SNPs were found in all introns except intron 5, of
which three have not previously been described (Table 4).
No polymorphisms were found in the minimal promoter or
in the 50UTR region and three known polymorphisms were
found in the 30UTR. Seven known SNPs, one in exon 6 and
six in exon 8, were identified in the coding sequence; five
do not result in amino-acid changes and two result in
amino-acid changes (Table 4).
Discussion
We have undertaken mutation analysis in seven Danish
families with WS and identified a mutation in 11/14
disease chromosomes (78.6%), which is comparable with
other reports.8 Two families were compound heterozygous
(EE32 and EE76), two families were homozygous (EE34 and
EE53), and in three families it was only possible to identify
one mutation (EE31, EE33, and EE77).
Four mutations, Q194X, L313fsX360, F883fsX951, and
H313Y, have not been reported before. The first 3
mutations are likely to result in an impaired protein
function, whereas the functional consequences of the
missense mutation are uncertain. The mutation H313Y in
the TM1 domain (Figure 2a) has not been reported before,
but other mutations in TM1 (M312R and A326V) have
been reported in subjects with psychiatric disorder.22,23
Figure 2b shows alignment of WFS1 from six different
organisms, two primates, two rodents, one bird, and one
fish. The overall conservation for WFS1 between the
species is 99–56%, and higher in the ER lumen C-terminal
than in the cytoplasmatic N-terminal (data not shown). All
the identified mutations affect conserved amino acids
among the six organisms in the WFS1, protein with the
exception of two that differs in Fugu (Figure 2b).
Identification of a mutation in the WFS1 coding region
in only one allele in three of the families implies that a
second disease-causing mutation has escaped detection
(Table 2).
The missing mutation could be one of the identified
polymorphisms leading to either decreased stability or
translation of the mRNA product or alternative splice forms
of the WFS1 mRNA, both phenomena leading to either
a nonfunctional or an absent WFS1 protein. The poly-
morphisms V395V, H611R, K811K, and S855S found in
EE31 and EE33 are all associated with psychiatric disorders
alone or in combination with either DM and sensorineural
hearing impairment, DM type I, or DM type II.24 – 27 The
cis- or trans-location of the identified polymorphisms as
well as their possible influence on phenotypes are un-
known. The SNP Ivs415T4C is located so close to the
intron4–exon5 border, that it might interfere with the
intron–exon splicing. This SNP is heterozygous in family
EE31, EE33, and EE77, but also in the compound hetero-
zygous family EE76. A second mutation may also be
located in the promoter regions or in other cis- or trans-
acting regulatory elements. Furthermore, mutations may
also occur in the second WS locus, WFS2, at 4q22–q24.6
The occurrence of the mutation H313Y de novo in two
unrelated families (EE33 and EE77) is a surprising finding,
considering the fact that de novo mutations seem to be very
rare in WSF1.8 The phylogenetic conservation of H313
(Figure 2b) and the restriction enzyme RsaI analysis of 60
control persons support the causative role of the sequence
change, c.937C4T. Hypothetically, H313Y may act as a
dominant-negative mutation analogous to dominant mu-
tations in LFSNHL. WS mutations are in general inactivat-
ing ‘loss-of-function’ mutations as nonsense or frame shift
mutations,8 whereas mutations found in combination with
AD LFSNHL are small noninactivating ‘gain-of-function’
mutations.28
In spite of selection criteria precluding cases of WS
without DM or OA, considerable phenotypic variability is
noticed even among the few cases in the present material.
However, we found less intrafamilial variation than
between patients from different families.
In addition to the classical quartet defining the DID-
MOAD syndrome, our sample included patients with
neuro-endocrine abnormalities, including growth retarda-
tion, delayed puberty, and primary amenorrhoea. The
possibility of a normal reproductive function was illu-
strated by the fact that one female and two males over the
age of 25 years had children. The presence of cataract in
five patients is in line with a growing number of reports
indicating that cataract should be considered a more
regular part of WS than hitherto recognized.29 – 32
No firm correlation between genotypes and phenotypes
has emerged so far despite the large number of reported WS
subjects with specified WFS1 mutations. Hardy et al21
reported on four British families with a 4-bp deletion at
position 2648 (2646 in the nomenclature used by us) and
suggested that brain stem atrophy with severe respiratory
involvement was associated with this homozygous muta-
tion, resulting in a chimeric 949 aa wfs1 protein.21,33 In
fact, a cerebral MRI in EE34:II.3 with a similar homozygous
1-bp mutation showed a slender brain stem, but no
respiratory symptoms were reported in any of the two
affected brothers in this family. In addition to severe OA,
they had well-regulated DM without signs of diabetic
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retinopathy after 37 and 28 years duration, but neither
hearing impairment nor diabetes insipidus or other neuro-
endocrine abnormalities. Since both affected persons in
family EE34 thus demonstrated a mild WS phenotype, it is
tempting to hypothesize that the extended chimeric wfs1
found in EE34 may retain part of its function, resulting in
milder symptoms in the homozygous state.
None of the present probands had the mt-DNA A3243G
mutation or the A1555G mutation (data not shown),
which has been postulated to possibly influence the
severity of the individual WFS1 mutations in different
patients. Our negative findings are in line with the absence
of mtDNA mutations reported by others.34,35
Audiometry on the WS patient from family EE32 with
two missense mutations in exon 4 and exon 8 showed HL
of 30 dB at 6000 Hz and 60 dB at 8000 Hz. This subject was
one of two with DI. The second DI patient, EE76:II.2, also
had hearing impairment affecting primarily the high
frequencies (HF) hearing deficiency. Both affected sisters
in family EE53 had hearing impairment affecting low and
high frequencies, but better preservation of hearing in the
mid-frequencies. Their hearing problems, however, might
in part be conductive due to middle ear pathology. Both
probands with the de novo H313Y mutation, EE33 and
EE77, had congenital profound hearing impairment, but
only one of them, EE77:II.1, had mental retardation, again
showing clinical variability. It would be of great prognostic
significance to be able to assess the functional implications
of different WFS1 mutations along with increasing under-
standing of the normal function of the wolframin protein.
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